Relation of animal husbandry to human nutritional needs.

N. Wright

Proceedings of The Nutrition Society

Abstract:

What problem does this paper attempt to address?

Accuracy, User Acceptability, and Safety Evaluation for the FreeStyle Libre Flash Glucose Monitoring System When Used by Pregnant Women with Diabetes

Eleanor M. Scott,Rudy W. Bilous,Alexandra Kautzky-Willer

DOI: https://doi.org/10.1089/dia.2017.0386

2018-03-01

Abstract:BACKGROUND: Accuracy of the FreeStyle Libre™ Flash Glucose Monitoring System has not been evaluated in pregnant women with diabetes. The aim of this study was to determine accuracy (compared to self-monitoring of blood glucose [SMBG]), clinical safety, and acceptability of the FreeStyle Libre System when used at home by this population.MATERIALS AND METHODS: Seventy-four participants, with type 1 (T1D, n = 24), type 2 (T2D, n = 11), or gestational (n = 39) diabetes, were enrolled across 13 sites (9 in United Kingdom, 4 in Austria). Average gestation was 26.6 ± 6.8 weeks (mean ± standard deviation), age was 30.5 ± 5.1 years, diabetes duration was 13.1 ± 7.3 years for T1D and 3.2 ± 2.5 years for T2D, and 49/74 (66.2%) used insulin to manage their diabetes. Sensors were worn for up to 14 days. Sensor glucose values (masked) were compared with capillary SMBG values (made at least 4 times/day).RESULTS: Clinical accuracy of sensor results versus SMBG results was demonstrated, with 88.1% and 99.8% of results within Zone A and Zones A and B of the Consensus Error Grid, respectively. Overall mean absolute relative difference was 11.8%. Sensor accuracy was unaffected by the type of diabetes, the stage of pregnancy, whether insulin was used, age or body mass index. User questionnaires indicated high levels of satisfaction with sensor wear, system use, and comparison to SMBG. There were no unanticipated device-related adverse events.CONCLUSIONS: Good agreement was demonstrated between the FreeStyle Libre System and SMBG. Accuracy of the system was unaffected by patient characteristics, indicating that the system is safe and accurate to use by pregnant women with diabetes.

endocrinology & metabolism
Evaluation of the FreeStyle® Libre Flash Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes

Guy G Massa,Inge Gys,Anniek Op 't Eyndt,Esmiralda Bevilacqua,Anne Wijnands,Peter Declercq,Renate Zeevaert

DOI: https://doi.org/10.1159/000487361

Abstract:Background/aims: The FreeStyle® Libre Flash Glucose Monitoring System (FGM, Abbott) measures glucose concentrations in the interstitial fluid for up to 14 days. It has been approved for use in children aged > 4 years in January 2016. Experience in children is still limited. We evaluated the accuracy and usability of the FGM in children with type 1 diabetes mellitus (DM). Methods: 67 children with type 1 DM (35 girls), aged 4-18 years, were included. Subjects wore a sensor on the back of their upper arm. For the first 14 days, they regularly measured capillary blood glucose (BG) with their usual BG meter (Accu-Chek® Mobile [ACM], Roche [n = 24]; Contour® Next Link [CNL], Bayer [n = 26]; OneTouch® Verio® IQ [OTV], LifeScan [n = 17]) followed by a sensor glucose (SG) scanning. SG readings were compared to BG measurements by consensus error grid (CEG) analysis; the mean difference (MD), the mean relative difference (MRD), the mean absolute difference (MAD), and the mean absolute relative difference (MARD) were calculated. After 14 days, subjects were asked to fill in a questionnaire on the usability of the FGM. Results: 2,626 SG readings were paired with BG results. FGM readings were highly correlated with BG (r = 0.926, p < 0.001). 80.3% of the data pairs were in zone A (= no effect on clinical action) and 18.4% were in zone B (= altered clinical action with little or no effect on the clinical outcome) of the CEG. Overall MD was +7.5 mg/dL; MD varied with the BG meter: ACM +10.4 mg/dL, CNL +14.2 mg/dL, OTV -3.6 mg/dL (p < 0.001). Overall, MARD was 16.7%. We observed a large interindividual variability in the accuracy parameters. MD and MRD were inversely related to BMI (r = -0.261 [p < 0.05]; r = -0.266 [p < 0.05], respectively). MARD was inversely related to age (r = -0.266 [p < 0.05]). Twenty-nine patients (43.3%) reported sensor problems, mainly early detachment of the sensor. Nonetheless, the usability questionnaire indicated high levels of satisfaction. Conclusions: Our results showed a reasonable agreement between the FGM SG readings and capillary BG measurements in children. There was, however, a large interindividual variability. The wearing of the sensor requires special attention. Further studies in children are imperative in order to document the accuracy and safety of the FGM in the paediatric population.
High-resolution imaging by wave-front conjugation.

M. Levenson

DOI: https://doi.org/10.1364/OL.5.000182

IF: 3.6

1980-05-01

Optics Letters

Abstract:Conjugate-wave-front generation by degenerate four-wave mixing is used to produce images with a resolution better than 500 lines/mm with 514.5-nm light.
Flash glucose monitoring in gestational diabetes mellitus (FLAMINGO): a randomised controlled trial

Majewska, Agata

DOI: https://doi.org/10.1007/s00592-023-02091-2

2023-05-11

Acta Diabetologica

Abstract:Aims Gestational diabetes mellitus (GDM) is the most common type of hyperglycaemia in pregnancy. GDM is a risk factor of adverse perinatal outcomes, with the incidence rate increasing proportionally to the level of maternal dysglycaemia. Therefore, glycaemic control plays an important role in management of GDM. The aim of this study was to assess the efficacy of flash glucose monitoring (FGM) in GDM. Materials and methods This was a non-blinded, randomised controlled trial, that recruited 100 pregnant women diagnosed with GDM between 24 and 28 weeks of gestation at the 1st Department of Obstetrics and Gynaecology, Medical University of Warsaw. After meeting the inclusion criteria patients were randomly allocated to the study group (FGM, n = 50) or control group (self-monitoring of blood glucose—SMBG, n = 50). Clinical and laboratory results were assessed at four follow-up visits. The primary outcome was mean fasting and postprandial glycaemia. The secondary outcomes were perinatal outcomes. Results There was no significant difference in mean glycaemia between the groups ( p = 0.437) Compared to the control group, the study group significantly reduced their fasting ( p = 0.027) and postprandial glycaemia ( p = 0.034) during the first 4 weeks following GDM diagnosis, with no significant difference in progression to insulin therapy (OR 1.09, 95% CI 0.47–2.57) Incidence of fetal macrosomia was significantly higher in SMBG as compared to FGM group (OR 5.63, 95% CI 1.16–27.22). Conclusions Study results indicate that FGM has an impact on glycaemic control, dietary habits and incidence of fetal macrosomia in patients with GDM. Trial registration clinicaltrials.gov ID : NCT04422821.

endocrinology & metabolism
Analytical Performance of the Factory-Calibrated Flash Glucose Monitoring System FreeStyle Libre2TM in Healthy Women

Zhuoxiu Jin,Alice E. Thackray,James A. King,Kevin Deighton,Melanie J. Davies,David J. Stensel

DOI: https://doi.org/10.3390/s23177417

IF: 3.9

2023-08-26

Sensors

Abstract:Continuous glucose monitoring (CGM) is used clinically and for research purposes to capture glycaemic profiles. The accuracy of CGM among healthy populations has not been widely assessed. This study assessed agreement between glucose concentrations obtained from venous plasma and from CGM (FreeStyle Libre2TM, Abbott Diabetes Care, Witney, UK) in healthy women. Glucose concentrations were assessed after fasting and every 15 min after a standardized breakfast over a 4-h lab period. Accuracy of CGM was determined by Bland–Altman plot, 15/15% sensor agreement analysis, Clarke error grid analysis (EGA) and mean absolute relative difference (MARD). In all, 429 valid CGM readings with paired venous plasma glucose (VPG) values were obtained from 29 healthy women. Mean CGM readings were 1.14 mmol/L (95% CI: 0.97 to 1.30 mmol/L, p < 0.001) higher than VPG concentrations. Ratio 95% limits of agreement were from 0.68 to 2.20, and a proportional bias (slope: 0.22) was reported. Additionally, 45% of the CGM readings were within ±0.83 mmol/L (±15 mg/dL) or ±15% of VPG, while 85.3% were within EGA Zones A + B (clinically acceptable). MARD was 27.5% (95% CI: 20.8, 34.2%), with higher MARD values in the hypoglycaemia range and when VPG concentrations were falling. The FreeStyle Libre2TM CGM system tends to overestimate glucose concentrations compared to venous plasma samples in healthy women, especially during hypoglycaemia and during glycaemic swings.

engineering, electrical & electronic,chemistry, analytical,instruments & instrumentation
Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network

K. Hori,Norihiro Kobayashi,H. Atsumi,A. Nagayama,Masako Kondoh,Ichiro Noge,M. Kimura,Hiroaki Utsugi,Tsuyoshi Iwasaki,Masaki Nakamura,Tomomi Kimura

DOI: https://doi.org/10.1007/s00520-013-2048-4

IF: 3.1

2014-04-01

Supportive Care in Cancer

Abstract:
Flash Glucose Monitoring to Assess Glycemic Control and Variability in Hemodialysis Patients: The GIOTTO Study

Emanuele Mambelli,Stefania Cristino,Giovanni Mosconi,Christian Göbl,Andrea Tura

DOI: https://doi.org/10.3389/fmed.2021.617891

IF: 3.9

2021-07-30

Frontiers in Medicine

Abstract:Background: Flash glucose monitoring (FGM) is a technology with considerable differences compared to continuous glucose monitoring (CGM), but it has been scarcely studied in hemodialysis patients. Thus, we aimed assessing the performance of FGM in such patients by comparison to self-monitoring of blood glucose (SMBG). We will also focus on estimation of glycemic control and variability, and their relationships with parameters of glucose homeostasis. Methods: Thirty-one patients (20 with type 2 diabetes, T2DM, 11 diabetes-free, NODM) collected readings by FGM and SMBG for about 12 days on average. Readings by FGM and SMBG were compared by linear regression, Clarke error grid, and Bland-Altman analyses. Several indices of glycemic control and variability were computed. Ten patients also underwent oral glucose tolerance test (OGTT) for assessment of insulin sensitivity/resistance and insulin secretion/beta-cell function. Results: Flash glucose monitoring and SMBG readings showed very good agreement in both T2DM and NODM (on average, 97 and 99% of readings during hemodialysis in A+B Clarke regions, respectively). Some glycemic control and variability indices were similar by FGM and SMBG ( p = 0.06–0.9), whereas others were different ( p = 0.0001–0.03). The majority of control and variability indices were higher in T2DM than in NODM, according to both FGM and SMBG ( p = 0.0005–0.03). OGTT-based insulin secretion was inversely related to some variability indices according to FGM ( R < −0.72, p < 0.02). Conclusions: Based on our dataset, FGM appeared acceptable for glucose monitoring in hemodialysis patients, though partial disagreement with SMBG in glycemic control/variability assessment needs further investigations.

medicine, general & internal
Evaluation of Blood Glucose Meter Efficacy in an Antenatal Diabetes Clinic

Rachel T McGrath,Vanessa C Donnelly,Sarah J Glastras,Veronica A Preda,Nisa Sheriff,Peter Ward,Samantha L Hocking,Gregory R Fulcher

DOI: https://doi.org/10.1089/dia.2015.0104

Abstract:Background: The optimal treatment of diabetes in pregnancy requires accurate measurement of blood glucose levels, in order to minimize adverse outcomes for both mother and neonate. Self-monitoring of blood glucose is routinely used to measure glycemic control and to assess whether treatment targets are being met; however, the accuracy of blood glucose meters in pregnancy is unclear. Materials and methods: Pregnant women with gestational, type 1, or type 2 diabetes mellitus were eligible to participate. Nonfasting capillary blood glucose levels were measured in duplicate using the BGStar(®) (Sanofi, Sydney, Australia) and FreeStyle Lite(®) (Abbott, Sydney) blood glucose meters. Venous blood samples were collected and analyzed for plasma glucose, hematocrit, and glycated hemoglobin. Capillary blood glucose was compared with plasma glucose and further assessed according to International Organization for Standardization (ISO) 15197:2013 standards. Results: One hundred ten women were recruited, providing 96 samples suitable for analysis. The mean ± SD laboratory plasma glucose level was 4.6 ± 1.4 mmol/L; the BGStar and FreeStyle Lite capillary blood glucose values were 5.3 ± 1.4 mmol/L and 5.0 ± 1.3 mmol/L, respectively. Both meters showed a positive bias (0.42 mmol/L for the FreeStyle Lite and 0.65 mmol/L for the BGStar). Furthermore, neither meter fulfilled the ISO 15197:2013 standards, and there was a nonsignificant improvement in meter performance at blood glucose levels of ≤4.2 mmol/L. Hematocrit did not affect the results of either blood glucose meter. Clarke Error Grid analysis demonstrated that approximately 70% of the results of both meters would lead to appropriate clinical action. Conclusions: The BGStar and FreeStyle Lite blood glucose meters did not meet ISO 15197:2013 recommendations for blood glucose monitoring systems when assessed in a population of women with diabetes in pregnancy. Clinicians should consider this difference in blood glucose readings when making diabetes-related treatment decisions.
Interrelationship Between Photoperiodic Behavior of Grapes & Growth of Plant Tissue Cultures.

G. Alleweldt,F. Radler

DOI: https://doi.org/10.1104/PP.37.3.376

IF: 7.4

1962-05-01

PLANT PHYSIOLOGY

Abstract:The growth pattern of plant tissue cultures depends to a high degree on the level of essential nutrients and hormones in the synthetic medium. Thus, the auxin concentration has a very pronounced effect on the formation of callus or roots in many explants (3). The growth activity is, furthermore, modified by internal factors, e.g. the physiological age of the stock plants (e.g. grapes 2). The growth of plant tissue cultures, therefore, is, controlled by exogenous and endogenous factors. Investigating problems in respect to photoperiodically controlled growth of different grape varieties (1) leads to the question whether a photoperiodic pretreatment of young grape plants alters the growth activity of stem segments prepared from such pretreated plants. The experiment reported here was designed to provide this information. Similar qualitative results were obtained in experiments repeated at different times of the season.
Bu4NI-Catalyzed Cross-Coupling between Sulfonyl Hydrazides and Diazo Compounds To Construct β-Carbonyl Sulfones Using Molecular Oxygen.

Yaxiong Wang,Liang Ma,Meihua Ma,Hao Zheng,Y. Shao,X. Wan

DOI: https://doi.org/10.1021/ACS.ORGLETT.6B02532

IF: 5.2

2016-09-20

Organic Letters

Abstract:A new cross-coupling reaction between sulfonyl hydrazides and diazo compounds has been established, leading to a variety of β-carbonyl sulfones in good yields. This methodology was distinguished by simple manipulation, easily available starting materials, and wide substrate scope. A plausible mechanism involving a radical process was proposed based upon the experimental observations and literature.
Impact Of Flash Glucose Monitoring On The Fear Of Hypoglycemia Phenomenon In Adults With Type 1 Diabetes

Pablo Rodríguez de Vera Gómez,Carmen Mateo-Rodríguez,Beatriz Rodríguez-Jiménez,Lucía Hidalgo-Sotelo,Mercedes Peinado-Ruiz,Eduardo Torrecillas del Castillo,Desireé Ruiz-Aranda,Isabel Serrano-Olmedo,Ángela Candau-Martín,Mª Asunción Martínez-Brocca

DOI: https://doi.org/10.1089/dia.2023.0370

2024-02-06

Diabetes Technology & Therapeutics

Abstract:Objective: To assess the clinical impact on quality of life and on fear of hypoglycemia (FoH) of flash glucose monitoring (FGM) systems in adults with type 1 diabetes (T1DM). Methods: Prospective quasi-experimental study with 12-month follow up. People with T1DM (18-80 years old) and self-monitoring by blood capillary glycemia controls (SMBG) were included. The FH15 questionnaire, a survey validated in Spanish in a comparable study population, was used to assess FoH. A cut-off point of 28 points was used for the diagnosis of FoH. Results: A total of 181 participants were included, with a prevalence of FoH of 69% (n=123). A mean reduction in FH15 score of -4 points (95%CI [-5.5; -3]; p<0.001) was observed, along with an improvement in quality of life (EsDQOL-test, -7 points [-10; -4], p<0.001) and satisfaction with treatment (DTSQ-s test, +4.5 points [4; 5.5], p<0.001). At the end of the follow-up, 64.2% of the participants improved FoH intensity, compared to 35.8% who scored the same or higher. This improvement in FoH status was associated with a higher time-in-range at the end of follow-up (p=0.003), as well as a lower time spent in hyperglycemia (p=0.005). Additionally, it was linked to high baseline FoH scores (p<0.001) and possessing a university degree (p=0.07). Conclusions: FGM is associated with an overall reduction of FoH in adults with T1DM, with an increase in their quality of life. Nevertheless, a significant percentage of patients may suffer a worsening of this phenomenon, with clinical repercussions and an impact on quality of life.

endocrinology & metabolism
Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis

Anders L Carlson,Timothy Dilon Daniel,Andrea DeSantis,Serge Jabbour,Esra Karslioglu French,Davida Kruger,Eden Miller,Kerem Ozer,Tom Elliott

DOI: https://doi.org/10.1136/bmjdrc-2021-002590

2022-01-01

Abstract:Introduction Evidence supporting use of continuous glucose monitoring in type 2 diabetes treated with basal insulin is unclear. This real-world study aimed to assess the impact on glycated hemoglobin (HbA1c) of flash glucose monitoring use in adults with type 2 diabetes managed with basal insulin. Research design and methods Medical records were reviewed for adult individuals with type 2 diabetes using basal insulin for ≥1 year with or without additional antihyperglycemic medication, HbA1c 8.0%–12.0% prior to FreeStyle Libre Flash Glucose Monitoring use for ≥90 days and an HbA1c measurement recorded between 90 and 194 days after device use. Exclusion criteria included utilization of bolus insulin. Meta-analysis data are from the current study (USA) and a similar Canadian cohort. Results Medical record analysis (n=100) from 8 USA study sites showed significant HbA1c decrease of 1.4%±1.3%, from 9.4%±1.0% at baseline to 8.0%±1.2% after device use, p<0.0001 (mean±SD). Meta-analysis of medical records from USA and Canada sites (n=191) showed HbA1c significantly decreased by 1.1%±0.14% (mean±SE), from baseline 9.2%±1.0% to 8.1%±1.1%, p≤0.0001, with moderate to high heterogeneity between sites (Q=43.9, I 2 =74.9, p<0.0001) explained by differences in baseline HbA1c between sites. The HbA1c improvement in both groups was observed by age group, body mass index, duration of insulin use and sex at birth. Conclusions In a real-world retrospective USA study and a meta-analysis of a larger USA and Canada cohort, HbA1c significantly reduced in basal insulin-treated type 2 diabetes, without bolus insulin initiation and following the commencement of flash glucose monitoring technology.

endocrinology & metabolism
Evaluation of FreeStyle Libre Flash Glucose Monitoring System on Glycemic Control, Health-Related Quality of Life, and Fear of Hypoglycemia in Patients with Type 1 Diabetes

Ayman A Al Hayek,Asirvatham A Robert,Mohamed A Al Dawish

DOI: https://doi.org/10.1177/1179551417746957

2017-01-01

Abstract:Background/objectives: In the current era of modern technology and the development of smart devices such as the flash glucose monitoring (FGM) systems, patients can easily monitor their glucose levels more frequently without any inconvenience. In this study, we evaluate the effect of FreeStyle Libre FGM system on glycemic control, hypoglycemia, health-related quality of life (QoL), and the fear of hypoglycemia (FOH) among children and young people with type 1 diabetes (T1D). Design and methods: A prospective study was conducted at the Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia, between January 2017 and May 2017 on 47 (aged 13-19 years) registered patients with T1D who used conventional finger-pricking method for self-testing the glucose. At baseline visit, the FGM sensors were placed on each participant by a trained diabetes educator. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total number of scans conducted during the study period. At the baseline and at 3 months of the experiment, a trained interviewer administered the questionnaire Hypoglycemia Fear Survey-Child Version (HFS-C) and PedsQL 3.0 (QoL questionnaire) to each patient. The age, sex, weight, height, adjusted body mass index, duration of diabetes, treatment modality, and glycosylated hemoglobin A 1c (HbA 1c ) levels of each patient were recorded. Results: As compared with the baseline, a significant improvement was noted in the behavior of FOH ( P = .0001), worry ( P = .0001), QoL ( P = .002), HbA 1c level ( P = .008), and hypoglycemia ( P = .023) at 3 months. Significant improvement was noted in the behavior ( P = .0001), worry ( P = .0001), QoL ( P = .003), HbA 1c level ( P = .014), and hypoglycemia ( P = .001) among the multiple-dose insulin injection–treated patients as compared with baseline. Significant improvement was noted in the behavior ( P = .0001), worry ( P = .0001), and hypoglycemia ( P = .001) among the insulin pump–treated patients as compared with baseline. A positive correlation was recorded in the behavior ( r = .47; P < .001), QoL ( r = .70; P < .001), and the mean number of FGM scans. A negative correlation was recorded in the worry ( r = −.43; P = .002), HbA 1c level ( r = −.58; P < .001), hypoglycemia ( r = −.65; P < .001), and the mean number of FGM scans. Conclusions: The frequent use of FGM scanning reduced the frequency of hypoglycemia, HbA 1c level, and worry and increased the behavior and QoL. As compared with self-testing by the conventional finger-pricking method, the use of FGM increased the frequency of self-testing and thus diabetes control.
Assessment of glucose meter performance at the antenatal diabetes clinic: exploration of patient-related and pre-analytical factors

Mariam Parwaiz,Helen Lunt,Christopher M Florkowski,Florence J Logan,Lindsay Irons,Carol Perwick,Christopher M A Frampton,M Peter Moore

DOI: https://doi.org/10.1177/0004563213487893

Abstract:Background: To assess glucose meter performance in a diabetes antenatal clinic, focussing on clinical and pre-analytical factors that might impact on the quantification of meter accuracy and precision. Methods: The Freestyle Lite and the Performa glucose meters were assessed by trained researchers. Finger stick glucose was measured and compared with plasma venous glucose, obtained from a concomitantly collected antecubital fossa sample. Venous plasma was separated on-site then sent to the laboratory for measurement of glucose using the hexokinase method (comparative method). Additional data collected included: (i) timing of and also (ii) quantity of last carbohydrate intake; (iii) time periods between collection, preparation and analysis of the venous sample; (iv) the haemolysis index of the plasma sample and (v) haematocrit. Results: There were 104 participants. Both meters fulfilled ISO 15197 standards, with 99% and 97% of Freestyle Lite and Performa results, respectively, falling within acceptable limits for this standard. Both meters showed minor proportional bias, reading low at higher glucose values. Consensus error grid analysis showed 100% of results from the Freestyle Lite and 99% from the Performa falling within Zone A, thus the observed differences in measured capillary and venous plasma glucose were sufficiently minor that they would have little effect on clinical action. No association was observed between [capillary-plasma] glucose difference and the five variables outlined above. Conclusions: The two glucose meters tested showed a reassuringly acceptable level of performance, when assessed by a research team in the setting of a diabetes antenatal clinic.
Analytical Performance of the FreeStyle Libre 2 Glucose Sensor in Healthy Male Adults

Eva Fellinger,Tom Brandt,Justin Creutzburg,Tessa Rommerskirchen,Annette Schmidt

DOI: https://doi.org/10.3390/s24175769

IF: 3.9

2024-09-05

Sensors

Abstract:Continuous Glucose Monitoring (CGM) not only can be used for glycemic control in chronic diseases (e.g., diabetes), but is increasingly being utilized by individuals and athletes to monitor fluctuations in training and everyday life. However, it is not clear how accurately CGM reflects plasma glucose concentration in a healthy population in the absence of chronic diseases. In an oral glucose tolerance test (OGTT) with forty-four healthy male subjects (25.5 ± 4.5 years), the interstitial fluid glucose (ISFG) concentration obtained by a CGM sensor was compared against finger-prick capillary plasma glucose (CPG) concentration at fasting baseline (T0) and 30 (T30), 60 (T60), 90 (T90), and 120 (T120) min post OGTT to investigate differences in measurement accuracy. The overall mean absolute relative difference (MARD) was 12.9% (95%-CI: 11.8–14.0%). Approximately 100% of the ISFG values were within zones A and B in the Consensus Error Grid, indicating clinical accuracy. A paired t-test revealed statistically significant differences between CPG and ISFG at all time points (T0: 97.3 mg/dL vs. 89.7 mg/dL, T30: 159.9 mg/dL vs. 144.3 mg/dL, T60: 134.8 mg/dL vs. 126.2 mg/dL, T90: 113.7 mg/dL vs. 99.3 mg/dL, and T120: 91.8 mg/dL vs. 82.6 mg/dL; p < 0.001) with medium to large effect sizes (d = 0.57–1.02) and with ISFG systematically under-reporting the reference system CPG. CGM sensors provide a convenient and reliable method for monitoring blood glucose in the everyday lives of healthy adults. Nonetheless, their use in clinical settings wherein implications are drawn from CGM readings should be handled carefully.

engineering, electrical & electronic,chemistry, analytical,instruments & instrumentation
Accuracy and User Performance Evaluation of a New, Wireless-enabled Blood Glucose Monitoring System That Links to a Smart Mobile Device

Timothy S. Bailey,Jane F. Wallace,Scott Pardo,Mary Ellen Warchal-Windham,Bern Harrison,Robert Morin,Mark Christiansen

DOI: https://doi.org/10.1177/1932296816680829

2017-02-01

Journal of Diabetes Science and Technology

Abstract:Background: The new Contour ® Plus ONE blood glucose monitoring system (BGMS) features an easy-to-use, wireless-enabled blood glucose meter that links to a smart mobile device via Bluetooth ® connectivity and can sync with the Contour TM Diabetes app on a smartphone or tablet. Methods: The accuracy of the new BGMS was assessed in 2 studies according to ISO 15197:2013 criteria. In Study 1 (laboratory study), fingertip capillary blood samples from 100 subjects were tested in duplicate using 3 test strip lots. In Study 2 (clinical study), 134 subjects with type 1 or type 2 diabetes enrolled at 2 clinical sites. BGMS results and YSI analyzer (YSI) reference results were compared for fingertip blood obtained by untrained subjects’ self-testing and for study staff–obtained fingertip, subject palm, and venous results. Results: In Study 1, 99.0% (594/600) of combined results for all 3 test strip lots fulfilled ISO 15197:2013 Section 6.3 accuracy criteria. In Study 2, 99.2% (133/134) of subject-obtained capillary fingertip results, 99.2% (133/134) of study staff–obtained fingertip results, 99.2% (125/126) of subject-obtained palm results, and 100% (132/132) of study staff–obtained venous results met ISO 15197:2013 Section 8 accuracy criteria. Moreover, 95.5% (128/134) of subject-obtained fingertip self-test results were within ±10 mg/dl (±0.6 mmol/L) or ±10% of the YSI reference result. Questionnaire results showed that most subjects found the BGMS easy to use. Conclusions: The BGMS exceeded ISO 15197:2013 accuracy criteria both in the laboratory and in a clinical setting when used by untrained subjects with diabetes.
Effects of Flash Glucose Monitoring on Glycemic Control in Participants with Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.

Yuan Gao,Min Zhou,Xuan Xu,Wen Yu Chen

DOI: https://doi.org/10.1016/j.jdiacomp.2022.108314

IF: 3.219

2022-01-01

Journal of Diabetes and its Complications

Abstract:Background: With the introduction of flash glucose monitoring (FGM) into the international market in 2014, academics worldwide are exploring whether this device improves glycemic control in participants with diabetes mellitus.Objective: A study was conducted in which participants were evaluated to determine the effect of FGM on gly-cemic control. Methods: From inception to April 9, 2022, we searched the Cochrane Library, PubMed, SinoMed, Embase, Web of Science, MEDLINE, CNKI, Wan Fang Data, and VIP databases to collect randomized controlled trials (RCTs) related to the effect of FGM on glycemic control in participants with diabetes mellitus. Outcomes included glycated hemoglobin, the occurrence of hypoglycemic events, fasting plasma glucose (FPG), and 2-h postprandial glucose (2hPG) levels. The statistical analysis was performed using R 4.1.3 software.Results: We included 19 studies involving 2013 participants, all of which were RCTs. Meta-analysis results revealed that compared to self-monitoring of blood glucose (SMBG), FGM significantly reduced glycated he-moglobin levels in participants with type 2 diabetes mellitus [mean difference = -0.74 [95 % CI-1.16, -0.32], P < 0.01] and type 1 diabetes mellitus combined with type 2 diabetes mellitus [mean difference = -1.14 [95 % CI -3.14, 0.87], P < 0.01], with a greater effect in participants aged <= 65 years with type 2 diabetes mellitus (mean difference = -1.38 [95 % CI-2.05, -0.72], P < 0.01). However, there was no effect of FGM on the improvement of glycated hemoglobin levels in patients with type 1 diabetes mellitus [P = 0.45]. Furthermore, fasting plasma glucose levels and 2-h postprandial glucose levels were significantly lower in FGM than SMBG, and the number of hypoglycemic events was also significantly lower. Conclusion: Comparing SMBG with FGM indicated that FGM improves fasting plasma glucose levels, 2-h post-prandial glucose levels, and glycated hemoglobin levels, and it reduces the number of hypoglycemic events.
Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System

Shridhara Alva,Ronald Brazg,Kristin Castorino,Mark Kipnes,David R Liljenquist,Hanqing Liu

DOI: https://doi.org/10.1007/s13300-023-01385-6

Abstract:Introduction: We have evaluated the performance of the FreeStyle Libre® 3 continuous glucose monitoring system (FSL3) compared to (1) the venous plasma reference for participants aged ≥ 6 years and (2) the fingerstick capillary blood glucose (BG) reference for pediatric participants aged 4 and 5 years. The analytical performance of the third-generation factory-calibrated FSL3 CGM system was compared to the plasma venous blood glucose reference using the YSI 2300 STAT PLUS Glucose and Lactate Analyzer (the YSI reference) and the self-monitoring blood glucose (SMBG) reference for participants aged ≥ 6 years and participants aged 4 and 5 years, respectively. Methods: A total of 108 participants aged ≥ 4 years with type 1 or type 2 diabetes from four sites in the USA were enrolled in the study. The data of 100 participants were ultimately evaluated. Adult participants (aged ≥ 18 years) participated in three in-clinic sessions, and pediatric participants (aged 4-17 years) participated in up to two in-clinic sessions, all stratified to provide data for days 1, 2, 3, 7, 8, 9, 12, 13 or 14 of sensor wear. Performance evaluation included accuracy measures, such as proportion of CGM values that fell within ± 20% or ± 20 mg/dL (1.1 mmol/L) of the reference glucose values, and difference measures, such as the mean absolute relative difference (MARD) between the CGM and reference values. Results: Data from the 100 study participants were analyzed. The overall MARD was 7.8%, and 93.4% of the CGM values were within ± 20% or ± 20 mg/dL of the YSI reference for participants aged ≥ 6 years, with 6845 CGM-YSI matched pairs. The performance was stable over the 14-day wear period. For participants aged 4-5 years, MARD was 10.0%, and 88.9% of the CGM values were within 20%/20 mg/dL compared to a SMBG reference. No serious adverse events were reported. Conclusions: The FSL3 CGM system demonstrated accurate performance across the dynamic glycemic range during the 14-day sensor wear period.
Regulation of NK92‐MI Cell Cytotoxicity by Substance P

W. Fu,B. Qin,A. P. Zhou,Q. Yu,Q. Huang,Z. Liang

DOI: https://doi.org/10.1111/j.1365-3083.2011.02550.x

2011-08-01

Scandinavian Journal of Immunology

Abstract:The neuropeptide substance P (SP) can regulate a number of immunological functions in vitro and in vivo and may regulate natural killer (NK) cell activity. Here, we investigated whether SP has a role in regulating NK92‐MI cell function in vitro, and how it influences NK cell activity. We found that SP dose dependently increased the cytotoxicity of NK92‐MI cells and had a maximal effect at a concentration of 10−12 and 10−10 m. Furthermore, the expression of cytotoxic‐associated molecules (perforin, granzyme) and activating receptor NKp46 [a member of natural cytotoxicity receptors (NCRs)] was observed to be upregulated by SP at optimal concentration, at which SP enhanced the cytotoxicity of NK92‐MI cells. Neurokinin‐1 receptor (NK‐1R), a functional receptor of SP, was found on NK92‐MI cells, and the observed effects of SP on NK92‐MI cells could be more partially blocked by an NK‐1R antagonist. Our data suggest that SP induces NK92‐MI cell cytotoxicity by directly increasing the expression of cytotoxic granules and upregulates NK92‐MI cell receptor‐mediated functions indirectly. Thus, SP may regulate NK cell function mainly through NK‐1R.
Transdermal slow-release long-acting isosorbide dinitrate for 'nutcracker' oesophagus: an open study.

A. Tursi,G. Brandimarte,G. Gasbarrini

2000-09-01

Abstract:

Relation of animal husbandry to human nutritional needs.

Accuracy, User Acceptability, and Safety Evaluation for the FreeStyle Libre Flash Glucose Monitoring System When Used by Pregnant Women with Diabetes

Evaluation of the FreeStyle® Libre Flash Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes

High-resolution imaging by wave-front conjugation.

Flash glucose monitoring in gestational diabetes mellitus (FLAMINGO): a randomised controlled trial

Analytical Performance of the Factory-Calibrated Flash Glucose Monitoring System FreeStyle Libre2TM in Healthy Women

Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network

Flash Glucose Monitoring to Assess Glycemic Control and Variability in Hemodialysis Patients: The GIOTTO Study

Evaluation of Blood Glucose Meter Efficacy in an Antenatal Diabetes Clinic

Interrelationship Between Photoperiodic Behavior of Grapes & Growth of Plant Tissue Cultures.

Bu4NI-Catalyzed Cross-Coupling between Sulfonyl Hydrazides and Diazo Compounds To Construct β-Carbonyl Sulfones Using Molecular Oxygen.

Impact Of Flash Glucose Monitoring On The Fear Of Hypoglycemia Phenomenon In Adults With Type 1 Diabetes

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis

Evaluation of FreeStyle Libre Flash Glucose Monitoring System on Glycemic Control, Health-Related Quality of Life, and Fear of Hypoglycemia in Patients with Type 1 Diabetes

Assessment of glucose meter performance at the antenatal diabetes clinic: exploration of patient-related and pre-analytical factors

Analytical Performance of the FreeStyle Libre 2 Glucose Sensor in Healthy Male Adults

Accuracy and User Performance Evaluation of a New, Wireless-enabled Blood Glucose Monitoring System That Links to a Smart Mobile Device

Effects of Flash Glucose Monitoring on Glycemic Control in Participants with Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.

Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System

Regulation of NK92‐MI Cell Cytotoxicity by Substance P

Transdermal slow-release long-acting isosorbide dinitrate for 'nutcracker' oesophagus: an open study.